Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Nishiguchi

Showing results (181-190 of 191) with videos related to

Pageof 20
Sort By:
Annals of Nuclear Medicine|September 8, 2001
Accessory spleen in the pelvis diagnosed by Tc-99m phytate scintigraphyS Nishiguchi, D Habu, H Ishizu, et al.
Journal of Viral Hepatitis|December 2, 2017
Low incidence of hepatitis B virus reactivation and subsequent hepatitis in patients with chronic hepatitis C receiving direct-acting antiviral therapyA Tamori, S Abiru, H Enomoto, et al.
Alcoholism, Clinical and Experimental Research|February 1, 1996
Effect of vitamin E deficiency on inhibition of liver regeneration by long-term administration of alcoholT Tanaka, Y Goto, M Imano, et al.
Annals of Internal Medicine|April 1, 2000
Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapyY Shiratori, F Imazeki, M Moriyama, et al.
Journal of Viral Hepatitis|September 13, 2012
Anti-interferon-α neutralizing antibody is associated with nonresponse to pegylated interferon-α plus ribavirin in chronic hepatitis CF Matsuda, Y Torii, H Enomoto, et al.
Journal of Viral Hepatitis|May 20, 2016
Resistance Analyses of Japanese Hepatitis C-Infected Patients Receiving Sofosbuvir or Ledipasvir/Sofosbuvir Containing Regimens in Phase 3 StudiesM Mizokami, H Dvory-Sobol, N Izumi, et al.
Annals of Internal Medicine|July 31, 1999
Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon TherapyH Yoshida, Y Shiratori, M Moriyama, et al.
Journal of Viral Hepatitis|August 2, 2016
Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein for patients with chronic hepatitis B and C: a comparative studyH Nishikawa, H Enomoto, Y Iwata, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|February 22, 2007
Development of hepatocellular carcinoma in patients with chronic hepatitis C who had a sustained virological response to interferon therapy: a multicenter, retrospective cohort study of 1124 patientsS Kobayashi, T Takeda, M Enomoto, et al.
Journal of Environmental Quality|January 8, 2008
Environmental risk assessment of genetically engineered herbicide-tolerant Zoysia japonicaT W Bae, E Vanjildorj, S Y Song, et al.
Pageof 20

Showing results (181-190 of 191) with videos related to

Sort By:
Pageof 20
Annals of Nuclear Medicine|September 8, 2001
Accessory spleen in the pelvis diagnosed by Tc-99m phytate scintigraphyS Nishiguchi, D Habu, H Ishizu, et al.
Journal of Viral Hepatitis|December 2, 2017
Low incidence of hepatitis B virus reactivation and subsequent hepatitis in patients with chronic hepatitis C receiving direct-acting antiviral therapyA Tamori, S Abiru, H Enomoto, et al.
Alcoholism, Clinical and Experimental Research|February 1, 1996
Effect of vitamin E deficiency on inhibition of liver regeneration by long-term administration of alcoholT Tanaka, Y Goto, M Imano, et al.
Annals of Internal Medicine|April 1, 2000
Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapyY Shiratori, F Imazeki, M Moriyama, et al.
Journal of Viral Hepatitis|September 13, 2012
Anti-interferon-α neutralizing antibody is associated with nonresponse to pegylated interferon-α plus ribavirin in chronic hepatitis CF Matsuda, Y Torii, H Enomoto, et al.
Journal of Viral Hepatitis|May 20, 2016
Resistance Analyses of Japanese Hepatitis C-Infected Patients Receiving Sofosbuvir or Ledipasvir/Sofosbuvir Containing Regimens in Phase 3 StudiesM Mizokami, H Dvory-Sobol, N Izumi, et al.
Annals of Internal Medicine|July 31, 1999
Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon TherapyH Yoshida, Y Shiratori, M Moriyama, et al.
Journal of Viral Hepatitis|August 2, 2016
Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein for patients with chronic hepatitis B and C: a comparative studyH Nishikawa, H Enomoto, Y Iwata, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|February 22, 2007
Development of hepatocellular carcinoma in patients with chronic hepatitis C who had a sustained virological response to interferon therapy: a multicenter, retrospective cohort study of 1124 patientsS Kobayashi, T Takeda, M Enomoto, et al.
Journal of Environmental Quality|January 8, 2008
Environmental risk assessment of genetically engineered herbicide-tolerant Zoysia japonicaT W Bae, E Vanjildorj, S Y Song, et al.
Pageof 20